Journal of diabetes investigation 2017 12 15() doi 10.1111/jdi.12789
Atorvastatin is usually used to decrease the amount of fatty substances in individuals with type 2 diabetes mellitus. However, it can cause side effects, such as breakdown of skeletal muscle tissue. This study focuses on the effects of atorvastatin on autophagy of the skeletal muscles in diabetic rats.
MATERIALS AND METHODS
Diabetes in rats in the diabetic (D) and atorvastatin (T) groups was induced using streptozotocin (65 mg/kg, intraperitoneal injection). Next, rats in the T group were treated with atorvastatin (10 mg/kg/d, intragastric administration), while rats in the control and D groups were given water. Additionally, the rats in T and D groups were fed a high-fat and high-sugar diet for 10 weeks. Subsequently, the histopathological changes, and expression levels of LC3-I/-II and p62 in the skeletal muscle specimens in the three groups were analyzed.
Rats in the T group had reduced lipid droplets and cholesterol and low-density lipoprotein (P < 0.05) levels than those in the D group. Disordered atrophic myocytes, incrassated vascular walls, and decreased cross-sectional area of type I fibers were found using HE and ATPase staining in the diabetic and atorvastatin groups. The mRNA and protein levels of LC3-II and the LC3-II/LC3-I ratio were increased in the T group compared with those in the other groups (P < 0.05), whereas the protein level of p62 showed the opposite trend. CONCLUSION
Atorvastatin enhanced the autophagy level of skeletal muscles to decrease lipid deposition, which possibly exacerbated myopathy.